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Abstract
Maintenance of redox balance is essential for normal cellular functions. Any perturbation
in this balance due to increased reactive oxygen species (ROS) leads to oxidative stress and
may lead to cell dysfunction/damage/death. Mitochondria are responsible for the majority
of cellular ROS production secondary to electron leakage as a consequence of respiration.
Furthermore, electron leakage by the cytochrome P450 enzymes may render steroidogenic
tissues acutely vulnerable to redox imbalance. The adrenal cortex, in particular, is well
supplied with both enzymatic (glutathione peroxidases and peroxiredoxins) and non-
enzymatic (vitamins A, C and E) antioxidants to cope with this increased production of ROS
due to steroidogenesis. Nonetheless oxidative stress is implicated in several potentially lethal
adrenal disorders including X-linked adrenoleukodystrophy, triple A syndrome and most
recently familial glucocorticoid deficiency. The finding of mutations in antioxidant defence
genes in the latter two conditions highlights how disturbances in redox homeostasis may
have an effect on adrenal steroidogenesis.
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Introduction
Reactive oxygen species (ROS) are derived from O2
and comprise molecules with varying oxidant properties.
At low concentrations, ROS modulate many cellular
processes through redox-dependent signalling, including
proliferation, differentiation, apoptosis, immune regu-
lation and cellular adaptation to stress (Ray et al. 2012,
Sena & Chandel 2012). A critical balance in redox status
needs to be maintained and this is achieved by numerous
interacting antioxidant pathways. Oxidative stress
occurs when this balance is disturbed. ROS can then
have deleterious effects on proteins, lipids and nucleic
acids, ultimately leading to cell damage and death.
Oxidative stress is implicated in a plethora of conditions
including neurodegenerative disorders, diabetes mellitus,
cardiovascular disease and ageing. Antioxidant defence
mechanisms are complex and can be specific to cell type
and furthermore to sub-cellular compartment. In compari-
son to many other tissues, including those with high
metabolic demand such as the liver and brain, the adrenal
cortex has high levels of several antioxidants, both
enzymatic and non-enzymatic. This investment is necess-
ary given the high turnover of lipid within the mito-
chondria and ROS production during steroidogenesis.
Disturbances in redox homeostasis within the adreno-
cortical environment may therefore have an effect on
steroidogenesis, as evidenced by several disorders of
adrenal insufficiency, including most recently familial
glucocorticoid deficiency (FGD).
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ROS generation in mitochondria
Mitochondria are responsible for the majority of cellular
ROS production secondary to electron leakage as a con-
sequence of respiration. During respiration, electrons are
transferred across to molecular oxygen to generate water via
the four complexes of the electron transport chain. The
electron–proton gradient established during this process is
used to generate energy in the form of ATP. As a result of
electron leakage at complex I (NADH dehydrogenase) and
complex III (cytochrome c reductase), a small percentage of
the molecular oxygen is converted to superoxide anions
(O2%
K) (Fig. 1). These superoxide anions can be protonated
to form strongly oxidant hydroxyl radicals (%OH) which can
cause oxidative modification of proteins and membrane
lipids. ROS can also modify key components of the electron
transport chain thereby further exacerbating electron
leakage and superoxide production. Dismutation, catalysed
by the superoxide dismutases (SODs), reduces superoxide
ions to hydrogen peroxide (H2O2). H2O2 can also contribute
to oxidative stress by reacting with free metals to form OH.
In addition, in comparison to O2%
K, which tends to remain
at the site of production, H2O2 readily traverses membranes
into other subcellular compartments where it may affect
signalling pathways.
Several compartment-specific antioxidant mechani-
sms are in place to target superoxide production.
Cytoplasmic copper/zinc-dependent SOD1 (CuZnSOD),
mutations of which are associated with the neurodegener-
ative disorder, amyotrophic lateral sclerosis, and mito-
chondrial matrix manganese-dependent SOD2 (MnSOD)
catalyse the conversion of superoxide anions into H2O2
(Fig. 1). H2O2 has preferential reactivity towards (seleno)
cysteine (Cys) residues in target proteins, and is detoxified
by members of the glutathione peroxidase (GPX) and
peroxiredoxin (PRDX) families, discussed later in this
review. The relative contribution of each of these enzymes
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Detoxification of mitochondrial superoxide species produced during electron leakage from the mitochondrial electron transport chain. The superoxide
radical O2%
K, produced from electrons (eK) leaked at complexes I and III of the mitochondrial electron transport chain, can be protonated to form H2O2, this
process of dismutation is catalysed by MnSOD. Mitochondrial H2O2 is detoxified by the thioredoxin and GSH systems, which require high concentrations of
nicotinamide adenine dinucleotide phosphate (reduced NADPH) provided by NNT. The flow of electron transfer from NADPH to PRDX3 and GPX, through
the various components of the thioredoxin and GSH systems, is shown in the figure. GSR, glutathione reductase; GSH, reduced glutathione; TXNRD2,
thioredoxin reductase 2; TXN2, thioredoxin 2; GLRX2, glutaredoxin 2; NNT, nicotinamide nucleotide transhydrogenase; PRDX3, peroxiredoxin 3;
GPX, glutathione peroxidase; MnSOD, manganese superoxide dismutase.
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may be tissue- and compartment-specific and determined
by the source of H2O2 and the expression levels of each
individual enzyme.
In addition to electron leakage during respiration,
other sources of superoxide production within the
mitochondria include reactions catalysed by xanthine/
xanthine oxidase, uncoupled nitric oxide synthases,
NADPH-dependent oxidases (NOXs) and, most pertinent
to the adrenal cortex, cytochrome P450 isoforms. The
P450 enzymes are involved in the biosynthesis of
cholesterol-derived steroidal compounds (Miller 2005).
In steroidogenic tissues, the levels of expression of P450
enzymes are approximately ten times higher than those of
the other electron transport chain proteins and electron
leakage in the P450 system can also contribute to ROS
production (Hanukoglu & Hanukoglu 1986, Hanukoglu
2006). P450 groups are represented by microsomal
cytochrome P450s present in the endoplasmic reticulum,
and mitochondrial cytochrome P450s present in the inner
mitochondrial membrane. Type 1 P450 isoforms present
in the mitochondria include P450scc (side-chain cleavage;
CYP11A1), which catalyses the conversion of cholesterol
to pregnenolone, and P450c11b (CYP11B1) responsible
for the b-hydroxylation of 11-deoxycortisol to cortisol
(Fig. 2). The reactions catalysed by these P450 enzymes
require NADPH as a reducing agent, in addition to
molecular oxygen. NADPH donates two electrons which
are transferred to P450 enzymes via two electron transfer
proteins, ferredoxin reductase (adrenodoxin reductase)
and then ferredoxin (adrenodoxin) (Ziegler et al. 1999,
Grinberg et al. 2000). Ferredoxin reductase is a flavin
adenine dinucleotide, containing flavoenzyme and is able
to accept both electrons from NADPH. These are then
passed one at a time to ferredoxin and finally to the P450
enzymes for hydroxylation of substrates, the order of
electron transfer is as follows (Hanukoglu 2006):
NADPH/ferrodoxin reductase/ferrodoxin/P450
In a tightly coupled system, all electrons from NADPH
are used in substrate hydroxylation; however, electron
transfer within the P450 system can be relatively
‘uncoupled’ or ‘leaky’, with the rate of electron leakage
varying depending on P450 subtype (Hanukoglu 2006).
Up to 40% of total electron flow in the P450c11b system,
catalysing the final step in cortisol synthesis, is directed to
ROS formation in comparison to 15% in the P450scc
system (Rapoport et al. 1995). Thus steroidogenesis,
particularly glucocorticoid production, contributes signi-
ficantly to cellular ROS production (Fig. 2). Type 2
microsomal P450 isoforms, catalysing all the other steps
in steroidogenesis, are present in the endoplasmic
reticulum and are reliant on P450 oxidoreductase and
NADPH for reduction (Miller 2005).
Adrenal cortex antioxidant defence
mechanisms
The adrenal cortex is particularly equipped to handle
the increased risk of oxidative stress. Several antioxidants,
both enzymatic and non-enzymatic, are highly expressed
in comparison to other tissues. Ascorbic acid (vitamin C),
which recycles a-tocopherol (vitamin A) radicals, is
present at the highest levels in the adrenal cortex (Hornig
1975), indeed endogenous ascorbic acid was first isolated
from adrenal tissue (Svirbely & Szent-Gyorgyi 1932).
Depletion of ascorbic acid secondary to vitamin A
deficiency in rats leads to adrenocortical degeneration
(Gruber et al. 1976). Other non-enzymatic antioxidants
present at high levels within the adrenal cortex include
vitamins A and E (Azhar et al. 1995).
As previously described, O2%
K radicals are converted
by SODs to H2O2. Mitochondrial H2O2 is further reduced
by two major thiol antioxidant systems dependent on
reduced glutathione (GSH) and the small protein thior-
edoxin 2 (TXN2), each system has several associated
proteins (Fig. 1). Reduced GSH and components of the
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Figure 2
Reactive oxygen species (ROS) production during steroidogenesis. The
import of cholesterol from the outer mitochondrial membrane (OMM)
to the inner mitochondrial membrane (IMM) is activated by STAR and
mediated by the translocator protein (TSPO)-associated multi-component
complex. This is followed by cholesterol side-chain cleavage to pregneno-
lone by P450scc (CYP11A1). The other steps in the steroidogenic pathway
are catalysed by cytochrome P450 isoforms in the endoplasmic reticulum
(ER). The final step in cortisol synthesis is catalysed by P450c11b (CYP11B1)
in the mitochondria, converting 11-deoxycortisol to cortisol. Electron
leakage during this process results in ROS production.
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TXN2 system are seen in abundance in the adrenal cortex
(Azhar et al. 1995, Watabe et al. 1999). Both TXN2
and GSH systems are dependent on the reducing power
of NADPH. NADPH supply within the mitochondria is
maintained by the proton pump nicotinamide nucleotide
transhydrogenase (NNT). Mutations in NNT have
recently been associated with FGD, discussed later in this
review (Meimaridou et al. 2012). Mitochondrial NADPH
stores can also be restored by mitochondrial dehydro-
genases including malate dehydrogenase and isocitrate
dehydrogenase.
GSH contributes significantly to maintenance of a
reduced cellular environment. Under physiological con-
ditions, a high reduced (GSH):oxidised glutathione (gluta-
thione disulphide (GSSG)) ratio is maintained. GSH,
synthesised in the cytosol, is transported into the
mitochondria by dicarboxylate and 2-oxoglutarate carriers
(Palmieri 1994). Within the mitochondria, GSH is
regenerated from GSSG by the enzyme GSH reductase
with NADPH as a cofactor. GSH acts as an electron donor
for the GPXs, members of the selenoprotein family, which
incorporate selenocysteine in their enzymatic catalytic
site. These selenocysteine residues are highly redox-
reactive and GPXs play an important role in the reduction
of H2O2 to water. Selenium content of the adrenal is high
and selenium is preferentially retained in this organ
during selenium deficiency (Behne & Hofer-Bosse 1984).
Indeed, selenium deficiency results in a significant
depletion of GPX activity and a reduction in steroidogen-
esis in an adrenal cell line (Chanoine et al. 2001). Eight
GPX isoforms have been identified in humans, GPX1
being the major isoform in most tissues, present primarily
in the cytosol but also in small amounts in the
mitochondria. Our unpublished data shows especially
high expression in the adrenal cortex. In the testes and
spermatozoa, the mitochondrial isoform of Gpx4 is the
most prevalent form, with its depletion causing male
infertility in mice (Imai et al. 2009).
Mammalian PRDXs also catalyse the reduction of
H2O2 and lipid peroxides, albeit less efficiently than the
GPXs. They comprise a family of six members, most of
which (PRDX1–5) use TXN as an electron donor. PRDX3
and PRDX5 are present within the mitochondria; PRDX3
is mitochondria-specific and is seen in abundance particu-
larly within the adrenal cortex, with a significant role in
H2O2 detoxification within the mitochondrial matrix. It is
estimated that PRDX3 is the catalyst for up to 90% of H2O2
generated within the matrix (Cox et al. 2010). During
H2O2 elimination, two reduced PRDX3 subunits are
converted to an oxidised disulphide-linked dimer that is
reduced again by the mitochondrial TXN2 system (Zhang
et al. 2007; Figs 1 and 3). TXN2 in turn is maintained in
reduced form by the mitochondrial selenoprotein, thior-
edoxin reductase 2 (Fig. 1). In parallel, GSH can work
together with glutaredoxin 2 in the mitochondria to also
reduce PRDXs (Hanschmann et al. 2010) (Fig. 1).
The catalytic Cys in the mammalian 2-Cys PRDX
enzymes (PRDX1–4) can undergo hyperoxidation to Cys
sulfinic acid (Cys-SO2
K), inactivating its peroxidase
function (Woo et al. 2003). This inactive sulfinic form
can be reduced back to the active form by sulfiredoxin,
also seen most abundantly within the adrenal gland (Kil
et al. 2012; Fig. 3). The only PRDX to be seen in sulfinic
form within the adrenal cortex is PRDX3 and this
inactivation of PRDX3 has recently been demonstrated
to trigger a series of events within the adrenocortical
environment (Kil et al. 2012). In both the murine and
bovine models, adrenocorticotropic hormone (ACTH)
stimulation increases inactivated sulfinic PRDX3, an
effect that is prevented by treatment with metyrapone,
a P450c11b (CYP11B1) inhibitor. This indicates that
H2O2 produced in this final step of cortisol synthesis is
mainly responsible for this hyperoxidation of PRDX3.
Inactivation of PRDX3 results in accumulation of H2O2
H2O
SH
SO2–
S
S
TXN2
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PRDX3
PRDX3
PRDX3
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Figure 3
Maintenance of reduced peroxiredoxin 3 (PRDX3-SH) by thioredoxin 2
(TXN2) and sulfiredoxin (SRX). PRDX3, in its reduced form, detoxifies H2O2
in the mitochondria. This process induces the formation of disulphide
PRDX3 which in turn is reduced back to PRDX3-SH by TXN2. With excessive
H2O2 PRDX3 is hyperoxidised to an inactive sulfinic form (PRDX3-SO2
K) and
this hyperoxidisation is reversed by SRX.
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which can diffuse into the cytosol, activating p38 MAPK
signalling pathways with subsequent suppression of
STAR protein synthesis and inhibition of steroidogenesis
(Kil et al. 2012). It has been proposed that this
mechanism of redox signalling exerts physiological
control over steroidogenesis at the level of the adrenal
gland, in addition to the well-characterised negative
feedback exerted by cortisol on the hypothalamic–
pituitary–adrenal (HPA) axis.
Oxidative stress and steroidogenesis
Steroidogenesis significantly contributes to mitochondrial
ROS production (Fig. 2) and in turn oxidative stress can
impede steroidogenesis. STAR protein is essential for the
transport of cholesterol across the mitochondrial
membrane and is the first and rate-limiting step of steroido-
genesis (Fig. 2). STAR is synthesised as a 37 kDa protein
which is cleaved to a 30 kDa form in the mitochondria. The
precise mechanism of cholesterol transfer across
the mitochondrial membrane remains unclear. STAR is
proposed to act in conjunction with a multi-component
complex on the outer mitochondrial membrane. This
complex includes the translocator protein (TSPO), voltage-
dependent anion channel 1, TSPO-associated protein 7
(PAP7, ABCD3) and protein kinase A regulatory subunit 1a
(PKAR1A) (Papadopoulos & Miller 2012). STAR mutations
in humans have a clear effect on steroidogenesis with a
phenotype ranging from severe lipoid congenital adrenal
hyperplasia (LCAH), involving both adrenal and gonadal
dysfunction to milder atypical or non-classic forms of
LCAH which can resemble FGD (Baker et al. 2006, Metherell
et al. 2009, Miller 2011). Mutations in other members of
this outer mitochondrial membrane complex have, as yet,
not been associated with human disease.
There is evidence that STAR is sensitive to both
physiological and pathophysiological levels of ROS.
Studies in Leydig cells, using H2O2 and agents such as
perfluorododecanoic acid, demonstrate a clear reduction in
the protein expression of the intramitochondrial (30 kDa)
form of STAR, in response to ROS (Diemer et al. 2003,
Shi et al. 2010). There is no clear consensus as to whether
ROS also have an effect at a transcriptional level as current
data are inconsistent. Evidence of an effect on other
key components of the steroidogenic pathway such as
3b-hydroxysteroid dehydrogenase and P450c11b are also
documented (Zhao et al. 2012, Prasad et al. 2013). P450c11
activity in cultured bovine adrenal cells and foetal human
adrenocortical cells decreases rapidly as a result of
oxidative damage and this inactivation may confer
protection given the propensity of the P450c11b system
to produce superoxide anions (Hornsby 1980). Recently,
an additional mechanism by which steroidogenesis may
be compromised by oxidative stress has been proposed in
the Leydig cell model. STAR-mediated trafficking of redox-
active cholesterol hydroperoxides results in mitochondrial
toxicity, rendering steroidogenic cells susceptible to
further oxidative insult (Korytowski et al. 2013).
Oxidative stress and adrenal insufficiency
in humans
Oxidative stress is implicated in several conditions
characterised by primary adrenal failure including
triple A syndrome, X-linked adrenoleukodystrophy
(ALD) and most recently FGD. Despite ubiquitous
expression of the proteins involved, in all three conditions
defects in antioxidant defence specifically affect
the adrenal. Mechanisms involving mitochondrial and
peroxisomal dysfunction in addition to defective nucleo-
cytoplasmic transport of DNA repair proteins and
antioxidants demonstrate how disturbances in redox
homeostasis in several subcellular compartments can
have an effect on steroidogenesis.
FGD and NNT deficiency
FGD is characterised by ACTH resistance and glucocorti-
coid deficiency, which may prove fatal if appropriate
treatment with corticosteroids is not instigated. The
majority of cases are caused by defects in ACTH signalling
within the adrenal, namely mutations in the ACTH
receptor, melanocortin 2 receptor (MC2R), and its
accessory protein MRAP (melanocortin receptor accessory
protein) (Clark et al. 1993, Metherell et al. 2005,
Meimaridou et al. 2013). Novel mechanisms have recently
been described in FGD, involving replicative and oxidative
stresses (Hughes et al. 2012, Meimaridou et al. 2012). These
include mutations in minichromosome maintenance
protein 4 (MCM4), a DNA replicase and NNT, encoding
NNT, a proton pump located in the inner mitochondrial
membrane (Hughes et al. 2012, Meimaridou et al. 2012).
NNT uses energy from the mitochondrial proton gradient
to regenerate NADPH from NADPC, using NADH pro-
duced in the tricarboxylic acid cycle. NNT couples the
production of NADPH to the rate of mitochondrial
metabolism and the production of ROS generated by the
electron transport chain. High concentrations of NADPH
are required by both the GSH and TXN systems for
detoxification of mitochondrial ROS. NADPH is also
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utilised by the electron transfer proteins ferredoxin
reductase and ferredoxin, critical for the reduction of the
P450 enzymes in steroidogenesis (Hanukoglu 2006). Thus
there are several mechanisms by which NNT deficiency
may affect steroidogenesis. NNT is widely expressed with
high levels apparent in the adrenal gland in both human
and mouse tissues (Meimaridou et al. 2012).
A substrain of C57BL6/J mice carries a spontaneous
Nnt mutation leading to a 5-exon deletion; partial-
deletion of the first domain of NNT, which binds NADH,
and four of the 14 transmembrane domains which
comprise the proton channel (Toye et al. 2005). This
substrain of C57BL6/J mice shows an increased sensitivity
to O2%
K/ H2O2, particularly in the absence of mito-
chondrial MnSOD (SOD2) and a deficiency in both
antioxidants results in death within 1–2 days (Huang
et al. 2006) due to dilated cardiomyopathy. Introduction
of a normal copy of Nnt into the Sod2K/K mice with the
C57BL6/J background confers improved cardiovascular
function during foetal development (Kim et al. 2010).
Adrenals from the Nnt-mutant substrain have been noted
to have slightly disorganised zona fasciculata with higher
levels of apoptosis than WTs (Meimaridou et al. 2012).
No differences in P450scc (CYP11A1) and P450c11b
(CYP11B1) distribution were seen between the two
substrains; however, the mutant mice had lower basal
and stimulated levels of corticosterone, though the
deficiency was not as marked as that seen in the human
disease (Meimaridou et al. 2012). Lentiviral short hairpin
RNA (shRNA)-knockdown of NNT in the human adreno-
cortical H295R cell line leads to increased levels of
mitochondrial ROS, a decrease in the GSH:GSSG ratio
and increased apoptosis (Meimaridou et al. 2012).
Extra-adrenal features have also been demonstrated in
this substrain of mice. Nnt-mutant mice have impaired
glucose tolerance with loss of glucose-dependent insulin
secretion and ATP production in isolated pancreatic islet
cells, reminiscent of a type 2 diabetes mellitus model
(Kulkarni et al. 2003, Toye et al. 2005). When fed on a
high-fat diet, C57BL/6J mice develop obesity, hypergly-
caemia and insulin resistance (Rossmeisl et al. 2003).
Interestingly, it has been demonstrated that whilst this
strain does have reduced insulin secretion and impaired
glucose tolerance in comparison to other strains of mice
with higher expression levels of NNT, the C57BL/6J mice
expressing the truncated protein have similar insulin
secretion and glucose tolerance to the C57BL/6N mice
expressing the full-length WT protein, though at lower
levels than other strains (Wong et al. 2010). This indicates
that it is low levels of NNT rather than the protein
truncation caused by the 5-exon deletion that has an
effect. This also raises the possibility that another enzyme
is able to functionally compensate for the loss of NNT in
the C57BL/6J mouse, this could explain the relative
preservation of steroidogenesis in this strain in compari-
son to the human phenotype. C57BL/6J mice have also
been shown to have a higher sensitivity to neurotoxic
agents (Hamre et al. 1999). There are currently no
published reports of extra-adrenal clinical manifestations
in patients with NNT mutations; however, careful clinical
surveillance is required for these patients given the
ubiquitous expression of NNT.
Triple A syndrome
Triple A syndrome (Allgrove syndrome) is a rare autosomal
recessive disease characterised by the triad of alacrima,
achalasia of the oesophageal cardia and primary adrenal
failure (Allgrove et al. 1978). Alacrima is the earliest and
most consistent sign with achalasia, occurring in about
75% of patients, the usual reason for referral. Adrenal
insufficiency develops gradually over the first decade of
life and may present later than the first two symptoms, but
in some cases may be the presenting symptom leading to
diagnosis of disease. This has led to the recommendation
that in cases of the presence of alacrima and at least one
more symptom of triple A syndrome, adrenal function
testing and molecular analysis should be performed
(Milenkovic et al. 2010). Glucocorticoid and adrenal
androgen production are affected and a proportion of
patients also go on to develop a mineralocorticoid
deficiency. Neurodegenerative disease, features of which
can include peripheral neuropathy, autonomic impair-
ment, pyramidal and bulbar dysfunction, cerebellar
and neuro-ophthalmological signs, occurs in w60% of
patients (Houlden et al. 2002, Dixit et al. 2011, Vallet et al.
2012). In more than 90% of cases, the defect is due to
mutations in the AAAS gene, with over 60 different
mutations described in the literature. The phenotype is
variable even within members of the same kindred and
no genotype–phenotype correlation has been identified
(Houlden et al. 2002, Huebner et al. 2002, Milenkovic
et al. 2010).
The AAAS gene product is the 60 kDa nuclear pore
complex (NPC) protein ALADIN (alacrima–achalasia–
adrenal insufficiency neurologic disorder). AAAS mRNA
and the ALADIN protein are ubiquitously expressed with
predominance in the adrenal and CNS structures in the
human and the rat (Handschug et al. 2001, Storr et al.
2005, Cho et al. 2009). ALADIN is the only nucleoporin to
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Review R PRASAD and others Oxidative stress and
adrenocortical insufficiency
221 :3 R68
http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-13-0346
 2014 The authors
Printed in Great Britain
Published by Bioscientifica Ltd
be associated with hereditary adrenal disease and the first
to be associated with hereditary neurodegenerative
disease. CNS disorders have since been described in two
other nucleoporinopathies, resulting from mutations in
Nup62 and RanBP2/Nup358, although the precise patho-
genic mechanisms are unclear (Basel-Vanagaite et al.
2006, Neilson et al. 2009, Neilson 2010). ALADIN’s role
at the NPC is unknown. Most naturally occurring AAAS
mutations result in mislocalisation of the abnormal
ALADIN protein (mainly into the cytoplasm), implying
that correct NPC targeting is vital for its function
(Krumbholz et al. 2006).
All the clinical features are progressive, suggesting a
degenerative process. Patient adrenal histology reveals
atrophy of the zona fasciculata and reticularis (Allgrove
et al. 1978). Oxidative stress may play a role in the
pathogenesis of this complex disease. Dermal fibroblasts of
triple A patients have higher basal intracellular ROS and
are more sensitive to oxidative stress than WT fibroblasts
(Hirano et al. 2006, Kiriyama et al. 2008, Kind et al. 2010).
Additionally in the dermal fibroblast model, failure of
nuclear import of DNA repair proteins, aprataxin and DNA
ligase I, and the antioxidant ferritin heavy-chain protein
(FTH1) has been described (Hirano et al. 2006, Storr et al.
2009). How these nuclear import defects lead to an
increase in intracellular ROS remains unclear. Increased
chromosomal fragility has also been reported (Reshmi-S-
karja et al. 2003), a finding that has also recently been
described in cases of FGD within the Irish traveller
community, caused by mutations in the DNA replicase
MCM4 (Hughes et al. 2012). Lentiviral-shRNA knockdown
of AAAS in H295R human adrenocortical cells and SH-
SY5Y human neuroblastoma cells renders them hypersen-
sitive to oxidative stress, with a decrease in the GSH/GSSG
ratio (Prasad et al. 2013). Furthermore, AAAS knockdown
in H295R cells affects the key components of the
steroidogenic pathway, STAR and P450c11b expression,
with an effect on cortisol production, an effect that is
partially reversed with antioxidant N-acetylcysteine treat-
ment (Prasad et al. 2013).
AaasK/K mice fail to show a similar phenotype to
triple A syndrome patients and are largely indistinguish-
able from WT mice (Huebner et al. 2006). No significant
difference in baseline ACTH and corticosterone measure-
ments was observed. Histology revealed no gross abnorm-
ality of the organs and the adrenals, ovary, testes,
oesophagus, pituitary and peripheral nerves had features
similar to those of the WT. Infertility seen in the female
AaasK/K mice was postulated to be related to problems
with the maturation of oocytes. Ultrastructurally, there
were no observable differences in the NPC (using kidney
and liver tissue; Huebner et al. 2006). Additionally, no
NPC structural differences were detected by immunocyto-
chemistry of embryonic dermal fibroblasts. These findings
indicate the functional redundancy of ALADIN, at least in
mice. ALADIN’s function at the NPC may therefore be
species-specific, certainly species-specific function of
nucleoporins has been demonstrated with other Nups
(Gigliotti et al. 1998, Grimaldi et al. 2007).
X-linked ALD
X-linked ALD is an inherited neurometabolic disorder,
incorporating progressive demyelination in the CNS,
axonopathy in the spinal cord and adrenal insufficiency
(Kemp et al. 2012). The disease is caused by mutations in
the ABCD1 gene on Xq28, encoding the ALD protein
(ALDP), a member of the peroxisomal ATP-binding
cassette (ABC) transporters. The disease is clinically
heterogeneous and the clinical phenotype can be variable
even within families. The three most common phenotypes
reported are isolated adrenal insufficiency; a late onset
slowly progressive disease adrenomyeloneuropathy in
which two-thirds of patients also have adrenal insuffi-
ciency; and a cerebral inflammatory demyelinating form
which can be fatal in early childhood (Kemp et al. 2012).
Adrenocortical insufficiency can be the presenting
symptom of adrenomyeloneuropathy years or even
decades before the onset of neurological symptoms
(Wichers-Rothers et al. 2005).
ALDP imports VLCFA-CoA esters into the peroxisome
for degradation by b-oxidation (van Roermund et al.
2008). Peroxisomes play an important role in lipid
metabolism and are in close communication with mito-
chondria. Human ABCD1 expression is abundant in the
adrenal gland, testis, liver, kidney, lung, placenta and
intestine and this is mirrored in mouse expression profiles
(Troffer-Charlier et al. 1998, Hoftberger et al. 2007). ALDP
protein expression is particularly high in cells charac-
terised by steroid hormone production (the adrenal gland
and testis; Hoftberger et al. 2007). Within the adrenal
gland, the highest expression is seen in the zona
fasciculata and zona reticularis, reflective of the areas
affected by the disease. Mutations in ABCD1 result in
abnormal accumulation of VLCFAs in plasma and various
tissues, predominantly in myelin sheath, adrenal cortex
and testis (Forss-Petter et al. 1997). Histology from both
the mouse model and human specimens indicates the
involvement of oxidative stress in the pathogenesis of the
disease, with the evidence of increased MnSOD and lipid
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peroxidation (Powers et al. 2005). Increased ROS pro-
duction, depletion of GSH and decreased mitochondrial
membrane potential in patient dermal fibroblasts have
been described (Fourcade et al. 2008). The precise
mechanism whereby the accumulation of VLFCAs leads
to the generation of free radicals is unclear and several
effects have been proposed (Galea et al. 2012). VLCFAs are
substrates of b-oxidation within the peroxisomes, a
process that aids acyl-CoA availability and subsequent
synthesis of plasmalogens, phospholipids with reported
antioxidant properties (Hayashi & Oohashi 1995, Khan
et al. 2008, Brites et al. 2009). Dysfunction within
peroxisomes can have effects on mitochondria, as both
organelles are in communication and generation of ROS
within peroxisomes can disturb the mitochondrial redox
balance (Ivashchenko et al. 2011). VLCFAs may also have
direct effects on mitochondrial function, and structural
abnormalities including lipid accumulation are seen
within the mitochondria in Abcd1K/K mice (Forss-Petter
et al. 1997). Diminished levels of NADH and ATP are seen
within the spinal cord of Abcd1K/K mice, indicating
defects in energy biosynthesis (Galino et al. 2011).
Incorporation of VLFCAs into plasma membranes may
also have deleterious effects affecting membrane proper-
ties and stability. In addition to effects on redox balance
within peroxisomes and mitochondria, it has been
proposed that VLCFAs may be involved in signalling
within the immune system exacerbating inflammation,
which in turn can have further effects on ROS and reactive
nitrogen species (RNS) generation (Galea et al. 2012).
Mouse models for X-linked ALD have been established,
involving knockout of the ABCD1 gene. Elevated levels of
VLCFAs are seen from 6 months of age in the nervous
system and adrenal gland; however, there is no overt
phenotype until 16 and 20 months of age, when locomotor
alterations are evident (Forss-Petter et al. 1997, Pujol et al.
2002, 2004). The model is thus able to recapitulate some of
the neurodegenerative aspects of the human disease. With
regards to adrenal function, similar to the triple A
syndrome mouse model, no effect is seen on corticosterone
production at either baseline or upon stress, although
histological changes including VLFCA accumulation and
increased MnSOD expression are seen in the adrenal cortex
(Forss-Petter et al. 1997, Lu et al. 2007).
Models of disease
In all three adrenal insufficiency conditions discussed,
mouse models of the disease do not faithfully recapitulate
the human phenotype. It is possible that additional
mechanisms of antioxidant defence exist within the
adrenocortical environment of the mouse, conferring
relative protection. Given the potential limitations of
mouse models for studies of the adrenal aspects of these
diseases, consideration should be given to other available
in vivo models for further investigation of precise
pathogenic mechanisms.
Non-human primate models such as Papio hamadryas
(baboons) and Macaca mulatta (rhesus monkeys) have
been used to study age-related changes in endocrine
function (Goncharova & Lapin 2004). These have an
advantage over rodents in that they produce DHEA/
DHEAS, with a steroidogenic profile therefore more
reflective of that in man. Similar to man, DHEA/DHEAS
production decreases significantly whilst glucocorticoid
production varies little with age (Ferrari et al. 2001,
Goncharova & Lapin 2004). However, older monkeys
exhibit reduced HPA axis sensitivity to glucocorticoid
regulation, with a delay in normalisation of the axis after
stimulation. This indicates impairment of negative feed-
back mechanisms, a phenomenon also observed in man.
These non-human primate models have been used to
study the effect of corticosteroids on antioxidant defence,
in the context of ageing (Goncharova et al. 2008a,b, 2013).
Circadian rhythmicity of SOD in erythrocytes correlates
well with the characterised rhythmicity of DHEAS and
cortisol (Goncharova et al. 2008b). Additionally, a similar
age-related flattening of these SOD circadian rhythms has
been observed, indicating a possible regulatory effect of
corticosteroids on antioxidant defence. Age-related
changes in stress responsiveness of SOD (increasing with
age) and GSH reductase (decreasing with age) have also
been described in non-human primate models (Gonch-
arova et al. 2008a). This in turn can lead to peroxide
oxidation of lipids, haemolysis of erythrocytes and a
diminished reliability of oxygen transport. These studies
indicate that corticosteroids themselves play a role in
regulating the activity of antioxidants such as SOD and
GSH reductase within erythrocytes.
Conclusion
ROS play an important physiological role in steroido-
genesis; however, in excess they can have deleterious
effects on adrenal function. Steroidogenesis itself increases
the generation of ROS, rendering the adrenal gland
susceptible to oxidative damage. Inherited defects in the
components of several different subcellular compartments
have been described in association with increased sus-
ceptibility to oxidative stress and adrenal insufficiency.
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The use and further development of techniques pertaining
to the detection of ROS in a site-specific manner will
provide further information on the specific cellular targets
involved. Further functional interrogation together with
careful phenotyping of the respective patient cohorts will
allow better understanding of the role of these proteins in
human biology. Given the ubiquitous expression of the
causative genes identified so far, this knowledge could be
invaluable in directing patient surveillance and could also
potentially provide targets for therapeutic intervention.
Antioxidant defence within the adrenal certainly warrants
further investigation and other components within
this pathway may prove to be causative in the aetiology
of as yet unaccounted for cases of primary adrenal
insufficiency.
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